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1  | INTRODUC TION
Since embryo freezing (EF) is performed by vitrification,1 frozen em-
bryo transfer (FET) is increasingly common.2 Its efficacy and safety 
with surplus embryo are well known.2 Some authors have recom-
mended the “freeze-all” strategy for all patients,3,4 while others 
have suggested using this strategy in selected groups of patients: 
women with preimplantation genetic diagnosis cycles5; or women 
with high ovarian response,6 polycystic ovarian syndrome,7,8 high 
progesterone levels,9 and conditions appearing during stimulation 
such as polyps,10 thin endometrium,11 or hydrosalpinges.12
Ovarian stimulation has been associated with a number of detri-
mental changes in the endometrium, impairing implantation. Some of 
these adverse effects are related to a hyperestrogenic state,13 the pro-
duction of reactive oxygen species,14 immunological changes in endo-
metrial natural killer cells and cytokines,15 and advanced endometrial 
maturation.16 The aforementioned adverse effects are one of the main 
reasons for “freeze-all” programs. Nonetheless, it has not been studied 
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Background: The decision of whether frozen embryo transfer (FET) should be per-
formed in the cycle immediately after OPU or at least one cycle later is controversial. 
FET could improve pregnancy rates in IVF; however, how much time is needed for the 
endometrium to return to optimal receptivity after ovarian stimulation is not known.
Methods: Electronic search in MEDLINE, EMBASE, and Cochrane Central Register of 
Controlled Trials to identify studies providing data on the influence of the interval be-
tween embryo freezing (or OPU) and FET in FET cycles published between January 
1, 2007, and February 1, 2020.
Main findings: Data analyzed indicated that in the immediate FET cycles, there was 
a trend to an increased biochemical pregnancy rate (RR = 1.08; CI = 1.00-1.18), 
whereas the clinical pregnancy rate was somewhat higher, but without reaching 
statistical significance (RR = 1.07; CI = 0.99-1.15). The live birth rate was similar in 
the two groups (RR = 1.05; CI = 0.95-1.15), as was the implantation rate (RR = 0.98; 
CI = 0.83-1.16). Stratifying by embryo stage or FET type (freeze-all or FET after failed 
fresh transfer) showed no differences.
Conclusion: Systematically delaying FET does not offer benefits to IVF outcomes. 
In addition, immediate transfer is associated with a nonsignificant trend to better 
clinical pregnancy rate and it also avoids the psychological effects of prolonging the 
stress on prospective parents.
K E Y W O R D S
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whether these detrimental changes persist in subsequent cycles. In 
particular, there are no prospective randomized trials assessing the in-
fluence of EF-embryo transfer (ET) interval on pregnancy rates (PRs). 
In this context, the ideal interval between embryo freezing and ET has 
not been established. In a Web-based study, reporting data from 179 
ART centers in 58 countries, the majority of responders (61%) pre-
ferred a washout period between fresh and FET cycles.17
In retrospective studies, some authors have found higher PRs 
when ET is performed in the immediately following menstrual cycle.18-
21 On the other hand, there have also been reports of better results 
when ET is delayed ≥ 1 menstrual cycle22 or better clinical results in 
delayed FET, though the difference did not reach significance,23 while 
others have reported no differences.9,12,24-27 Further, the differences 
in some of the reports that were reported in favor of immediate FET 
disappeared when controlling for associated variables.20
The aim of our study was to perform a systematic review of the 
literature and meta-analysis of results found concerning the influ-
ence of EF-FET interval on IVF pregnancy outcomes.
2  | MATERIAL S AND METHODS
The literature search was performed in MEDLINE, EMBASE, and 
Cochrane Central Register of Controlled Trials, with the following key 
words: "Time"+"interval"+"cycle"+"ivf" or "immediate"+"embryo"+ 
"transfer" or "immediate"+"vs"+"delayed"+"ivf" or "optimal"+"time"+ 
"between"+"ivf" or "delay"+"ivf"+"cycle" or “interval” +” trans-
fer”+ “IVF.” The search was restricted to articles published be-
tween January 1, 2007, and February 1, 2020, written in English or 
Spanish. In addition, reference lists of the publications included were 
screened. Our search was submitted to the PROSPERO database 
(CRD42020204072). The meta-analysis was performed following 
the PRISMA methodology.28
The inclusion criteria were as follows: (1) cycles of ovarian stim-
ulation for an IVF/ICSI in which at least one embryo was cryopre-
served; (2) performance of FET in a cycle other than the cycle in 
which oocyte pick-up (OPU) was performed; and (3) collection of 
data on IVF outcomes allowing comparison between at least two EF-
FET interval groups. Thus, two types of patients were included: (a) 
patients receiving fresh ET in the OPU cycle who did not become 
pregnant and received FET in a subsequent cycle, and (b) patients 
undergoing “freeze-all” protocols.
The exclusion criteria were as follows: (1) fresh transfers in the 
second ET; (2) non-human studies; (3) failure to report data on PRs; 
and (4) lack of data to allow comparisons by EF-ET interval.
2.1 | Data extraction
The following data were extracted from every article: author, pub-
lication year, country where the study took place, number of cycles 
included in the study, mean age of the women, number of oocytes 
retrieved, IVF management, endometrial preparation and luteal 
phase support, exclusion criteria, EF-FET interval(s), number of cryo-
preserved embryos transferred, frozen embryo outcomes (implanta-
tion rate, biochemical pregnancy, clinical pregnancy, live birth rate), 
and the study conclusions. In one case, the authors were contacted 
to obtain additional information.24 The search was conducted by the 
same investigator (SB).
2.2 | Study quality assessment
Two reviewers (RM and IP) used the Newcastle-Ottawa Scale (NOS) 
for observational studies to assess the quality of the manuscripts in-
cluded.29 With this scale, each category is rated by awarding a maxi-
mum of one star, except “comparability by design or analysis” for 
which two stars may be given. A maximum of nine points is assigned 
indicating the least risk of bias (Table S1).
2.3 | Statistical analysis
For the statistical analysis, the following were calculated: relative 
risk (RR) and the corresponding 95% confidence interval (CI), and 
the p-value for each parameter under study. For each parameter, a 
"forest plot" was used to present the RR and CI for each of the stud-
ies. The threshold for statistical significance was set at P < .05. The 
heterogeneity of the results was assessed with the χ2 and I2 tests.
Statistical analysis was performed with Stata 15.1
3  | RESULTS
The flow of studies through the review process is shown in a PRISMA 
diagram28 presented in Figure 1. The search strategy yielded 520 re-
cords (516 after removal of duplicates), of which 499 were excluded 
after reading of the title and/or abstract, indicating that they did not 
fulfill the selection criteria. Finally, 17 studies were screened and 12 
were included in the meta-analysis. The characteristics of studies 
excluded30-34 are listed in Table S2. All the studies included scored 
well on the NOS, achieving a score of between 7 and 9 (Table S1).
3.1 | Study characteristics
3.1.1 | Origin
Our search identified 12 studies, 11 of them corresponding to full-
length articles and 1 to an abstract.21 As we can see in Table 1, the 
12 studies included a total of 18 127 FET cycles (5457 immediate 
and 12 570 delayed) carried out in women from centers in 6 dif-
ferent countries (Belgium, Spain, Australia, China, Israel, USA, and 
Turkey). Ten of the publications reported single-center studies,9,19-27 
while one was based on a multisite IVF clinic18 and one12 included 
two centers.
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Two studies were performed by the same group, in different pop-
ulations.12,26 Regarding the size of the populations included, in two 
studies, >4000 cases were analyzed,18,24 and in five, <500.9,12,21-23 In 
one study, the interval comparison was made considering two differ-
ent populations separately, with data provided for: women receiving 
GnRH agonists and those receiving GnRH antagonists.24 Since no 
combined data were given, for the purpose of the meta-analysis, this 
research was considered as two different studies: He et al, GnRH ag-
onist protocol; and He et al, GnRH antagonist protocol. Most studies 
had data collection periods of 3-5 years, and all can be considered 
relatively recent (having been published between 2016 and 2020), 
except that of Maas et al.21
3.1.2 | Inclusion and exclusion criteria
There were six studies including only freeze-all patients,19,20,24-27 
four including only patients with FET after failure of a previous fresh 
ET9,12,21,22 and two including both freeze-all and previously failed 
fresh transfers18,23 (Table S3).
Six studies reported an upper limit of age in the inclusion criteria: 
>38 years,22 >40 years,23,24 >42 years,25 and >45 years.9,27 Four 
reported a lower limit: <18 years9,23 and <20 years.22,24
Eight studies excluded preimplantation genetic diagnosis/preim-
plantation genetic screening cycles,9,12,19,22,24-27 and five excluded 
donor oocyte cycles.9,12,19,24,26 The other inclusion/exclusion criteria 
are listed in Table 1.
3.1.3 | Intervals considered
In six studies, FET was considered immediate when performed 
within the first menstrual cycle after OPU, and delayed when per-
formed after at least 2 menses.12,19,20,22,23,27 Another author ap-
plied the same criteria but with the limit that in delayed ET, the 
transferred embryos were cryopreserved for less than 6 months24 
(Table S3).
Other authors established a cutoff of days for immediate and 
delayed transfer: start of the FET cycle of ≤22 or >22 days after 
OPU,9,26 fresh ET-FET interval of ≤50 and >50 days,21 and EF-FET 
interval of 25-35 days (1 cycle) or 50-70 days (2 cycles).18 In another 
study, the patients were grouped by time interval between OPU and 
FET [32-46, 47-61, 62-76, 77-91, and ≥92 days).25
3.1.4 | OPU cycle management
For the study published as an abstract, no data at all were provided 
concerning cycle management (Table 1).21 In other cases, regarding 
the management of the OPU cycle, for downregulation, one study 
used GnRH agonists in a long protocol,22 three studies used daily 
GnRH antagonists,12,25,26 one study used either GnRH agonists in a 
short protocol or priming with progestins,19 four studies used either 
GnRH agonists in a long protocol or daily GnRH antagonists,9,20,23,24 
and one study GnRH agonists or antagonists, reporting the data sep-
arately for these two groups.24 Further, in one study, three different 
F I G U R E  1   PRISMA flowchart [Colour 
figure can be viewed at wileyonlinelibrary.
com]
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protocols were used: boost GnRH agonists, GnRH agonists in a long 
protocol, or GnRH antagonists,18 while in another, six different pro-
tocols were used: ultra-short, short, long, and modified ultra-long 
GnRH agonist protocols, a GnRH antagonist protocol, or a mini-stim-
ulation protocol.27
Ovarian stimulation was performed with recombinant FSH 
and HMG in six studies.9,12,22,23,25-27 In two studies, moreover 
long-acting FSH was also employed.12,26 One study only reported 
the use of “exogenous gonadotropins”,20 while only recombinant 
FSH was used in two studies18,24 and only HMG was employed in 
another.19
Triggering was performed with recombinant hCG in three stud-
ies,9,22,26 with either recombinant hCG or urinary hCG in two,18,24 
with GnRH antagonist in one,12 and with hCG and/or GnRH antago-
nist in five.19,20,23,25,27
3.1.5 | FET cycle management
For the study published as an abstract, no data were given at all 
concerning the FET cycle management (Table 1).21 Concerning the 
FET cycle preparation, GnRH agonist or contraceptive pill pretreat-
ment was used in one study25 and GnRH agonist downregulation 
was given to some women in another.23 In the other publications, no 
mention was made of GnRH agonists or contraceptive pills for FET 
cycle preparation.
In four studies, some women underwent FET in a natural 
cycle18,23,24,27 or in a modified natural cycle,19 whereas in one study, 
all underwent transfer in a modified natural cycle.9
In five studies, some patients received exogenous estro-
gens. The dose used was specified in three studies employing 
oral estradiol, 2 mg/d,27 6 mg/d,18 or 8 mg/d,19 but not reported 
in two: one employing oral estradiol24 and the other oral and/
or transdermal estradiol.23 In four other studies, all the women 
received exogenous estrogens. The doses used were as follows: 
2 mg/d,12,26 4-6 mg,22 6 mg/d, or 150 mg/d transdermal estradiol 
hemihydrate.20
In another, all women received oral estradiol in a step-up proto-
col (dose of 2-4-8 mg).25 Lastly, in one report, a small proportion of 
patients underwent FET in a stimulated cycle.
Concerning luteal phase support, in three studies in which 
natural cycles were used, no mention was made of progesterone 
supplementation,18,24,27 whereas in one study, vaginal progester-
one was used (progesterone gel or micronized progesterone).23 
Regarding the two series of women undergoing modified natural 
cycle IVF, in one, ovulation was triggered with hCG and the lu-
teal phase supported by micronized vaginal progesterone (200-
400 mg/24 h) or a single daily application of progesterone gel, and 
in the other, ovulation was triggered with 5000 IU of urinary hCG 
and the luteal phase supported by 40 mg/d of dydrogesterone.19 
In studies in which exogenous estrogens were used, progester-
one supplementation was only given vaginally in five cases: with 
600 mg/d of micronized vaginal progesterone in one case,20 with 
vaginal micronized progesterone without stating the dose in two 
cases,12,26 with vaginal progesterone gel in one case,25 and with 
vaginal progesterone pessaries 400-800 mg/d or 8% progesterone 
gel in one case.18 In three cases, progesterone was administered 
intramuscularly: at the dose of 40 mg/d in one study24 and 20 mg/d 
in another,27 while the dose was not reported in the third.23 In one 
case, either vaginal micronized progesterone (200-300 mg/d) or 
intramuscular progesterone was used,22 and in another, the oral 
and vaginal routes were combined, women receiving both 40 mg/d 
of oral dydrogesterone and 400 mg/d of micronized vaginal pro-
gesterone.19 Regarding the few cases of FET in stimulated cycles, 
no specific mention was made to luteal phase support.27
In the study published as an abstract, no mention was made of 
progesterone supplementation.21
3.1.6 | Embryo characteristics
FET involved only cleavage stage embryos in two studies,20,27 only 
blastocysts in four,9,21,23,25 and both cleavage stage embryos and 
blastocysts in five.12,19,22,24,26 In one study, embryo development 
stage was not reported18 (Table S3).
3.2 | Homogeneity of study groups
3.2.1 | Age
In one study, the age was significantly higher in the immediate trans-
fer group,18 while in another, the age was significantly higher in the 
delayed transfer group.24 The resulting mean age was very similar in 
both groups (Figure 2A).
3.2.2 | Oocytes retrieved in the OPU cycle
The mean number of oocytes retrieved ranged from nearly 1119,26 to 
nearly 22.12 In all the studies, the mean number of oocytes retrieved 
was similar in the immediate and delayed transfer groups. The meta-
analysis showed no statistical differences (Figure 2B).
3.2.3 | Transferred embryos
In three studies, the number of embryos transferred in the FET cycle 
was significantly higher in delayed transfers,9,12,18 whereas in eight, 
there were no significant differences.19-24,26,27 In one study, the 
mean number of embryos transferred was not reported, although 
it was stated that the frequency of single blastocyst transfer was 
similar in both groups.25 The meta-analysis showed no statistical dif-
ferences (Figure 2C).
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Number of cycles 
(immediate + delayed 
transfers) Age (y) OPU cycle management
Endometrial preparation/ luteal 
phase support
Day of embryo 
development Inclusion criteria Exclusion criteria
He et al 2020 (2014-2017), 
China (Guangzhou)
RC 3110 GnRH 
agonist protocol 
(1585 + 1525)
IT:31.74 ± 4.33 DT: 
31.98 ± 4.23
Long GnRH agonist protocol (triptorelin 
[Diphereline])
Recombinant FSH (Gonal-F or Puregon)
Urinary HCG (uHCG) or recombinant HCG 
(Ovitrelle)
(a) Natural cycle
(b) Daily oral estradiol valerate tablets 
and 40 mg/d of intramuscular 
progesterone
D3 or D5 Age: 20-40 y
Normal menstrual cycle.
Basal FSH < 12 mIU/mL
First FET cycle after whole embryo 
freezing using vitrification method








Uncontrolled endocrine or immune 
disorders or other systemic diseases
1294
GnRH antagonist 
protocol (778 + 516)
IT:31.37 ± 4.03
DT: 31.53 ± 4.23
GnRH antagonist protocol (cetrorelix 
[Cetrotide])
Recombinant FSH (Gonal-F or Puregon)








IT: 36.0 (26.5-45.9) 
DT: 35.5(26.2-43.9) 
(P = .001)
Three GnRH analog protocols were used:
(a) Short GnRH agonist (Synarel) protocol
(b) GnRH agonist starting in the midluteal phase 
of the previous cycle
(c) GnRH antagonist (Cetrotide, Orgalutran) on 
day 5 or when the leading follicle was ≥ 14 mm
In all cases, ovarian stimulation was performed 
with rec FSH (400-600 UI/d) (Gonal, Puregon).
In all cases, the beginning of the cycle could  
be spontaneous or after the intake of 
contraceptive pills (30 μg ethinyl estradiol and 
150 μg levonorgestrel)
Triggering with HCG (Ovidrel or Pregnyl)
(a) Natural cycle
(b) Estradiol valerate 6 mg/ day and 
vaginal progesterone pessaries (400-
800 mg/d) or 8% progesterone gel
NR FET cycles with a prior fresh cycle (“fresh 
cycle- FET” interval = 25-35 d or 50-70 d)
Cases from before 2000 or after 
2014
FET preceded by another FET







RC 198 (118 + 80) IT: 32.8 ± 5.0 DT: 
34.1 ± 5.6
GnRH antagonist or agonist protocols.
Triggering with rec HCG
Modified natural cycle
Ovulation triggering with hCG
Vaginal progesterone: 400 mg 
Utrogestan/24 h or 200 mg 
Endometrin (Ferring) or a single daily 










Huang et al 2019 
(01/2013-12/2016),
China (Shanghai)
RC 2998 (280 + 2718) IT: 30.6 ± 4.3
DT: 30.9 ± 4.2
(a) GnRH agonist short protocol: 0.1 triptorelin 
(Decapeptyl; Ferring)
Ovarian stimulation with 150-225 hMG ( hMG; 
Anhui Fengyuan)
Triggering with 5000-10 000 IU of urinary hCG 
( hCG; Lizhu Pharmaceutical Trading)
(b) Progestin-primed ovarian stimulation (10 mg 
medroxyprogesterone acetate (Shanghai Xinyi 
Pharmaceutical)
Ovarian stimulation with hMG (150-225 hMG . 
Triggering with
(a) single use of 5000-1000 IU of urinary hCG,
(b) single dose of triptorelin (0.1-0.2 mg) or
(c) dual trigger with 1,000 IU of urinary hCG 
and 0.1 mg of triptorelin.
(a) Modified natural cycles were 
recommended ( in case of regular 
menstrual cycles)
Ovulation was triggered with 5,000 IU 
of urinary hCG.
Luteal phase was supplemented 
with 40 mg/d of dydrogesterone 
(Duphaston; Abbott)
(b) In irregular cycles 8 mg/d of oral 
micronized estradiol (Fematon, 
Abbott)
Luteal phase was supplemented with 
40 mg/d of oral dydrogesterone and 
400 mg/d of vaginal progesterone 
(Utrogestan)
Day 3-4 cleavage 
stage embryos 
or day 5-6 
blastocysts
Infertile women who underwent their first 
FET after the first IVF/ICSI cycle using 
the freeze-all policy




Uterine anomalies (congenital or 
acquired)
Donor sperm or testicular/epididymal 
sperm.
Moderate or severe ovarian OHSS 
during ovarian stimulation cycle
Embryo cryopreservation > 120 d
Core information missing in medical 
records
Donated oocytes
In vitro maturation oocytes
PGD
Kaye et al 2018 (2013-2016), 
USA
RC 344 (80 + 264) IT: 33.6 ± 3.8
DT: 33.52 ± 3.7
GnRH antagonist or agonist (leuprolide) + rFSH 
and/or, hMG (Gonal-F, Follistim, Menopur) + 
hCG (Pregnyl or Novarel) or GnRH agonist or 
both
Natural cycle and vaginal 
progesterone (Crinone; Merck; or 
Endometrin; Ferring)
or
GnRH agonist downregulation + oral 
and/or transdermal 
estradiol + intramuscular 
progesterone
Blastocyst Age: 18-40 y
(a) FET after a previous ovarian stimulation 
cycle with one failed fresh ET
(b) Freeze-all protocol (PGD, ovarian 
hyperresponse/ OHSS risk, progesterone 
rise, planned surgery, pregnancy 
contraindication, lack of suitable D5 with 
blastocyst cryopreservation on day 6, 
patient preference)
Patients without a stimulation cycle 
before FET (donated oocytes).
Patients in whom embryo freezing 
was performed 120 or more days 
before the FET
Endometrial biopsy or endometrial 
scratching in the cycle prior to ET
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Number of cycles 
(immediate + delayed 
transfers) Age (y) OPU cycle management
Endometrial preparation/ luteal 
phase support
Day of embryo 
development Inclusion criteria Exclusion criteria
He et al 2020 (2014-2017), 
China (Guangzhou)
RC 3110 GnRH 
agonist protocol 
(1585 + 1525)
IT:31.74 ± 4.33 DT: 
31.98 ± 4.23
Long GnRH agonist protocol (triptorelin 
[Diphereline])
Recombinant FSH (Gonal-F or Puregon)
Urinary HCG (uHCG) or recombinant HCG 
(Ovitrelle)
(a) Natural cycle
(b) Daily oral estradiol valerate tablets 
and 40 mg/d of intramuscular 
progesterone
D3 or D5 Age: 20-40 y
Normal menstrual cycle.
Basal FSH < 12 mIU/mL
First FET cycle after whole embryo 
freezing using vitrification method








Uncontrolled endocrine or immune 
disorders or other systemic diseases
1294
GnRH antagonist 
protocol (778 + 516)
IT:31.37 ± 4.03
DT: 31.53 ± 4.23
GnRH antagonist protocol (cetrorelix 
[Cetrotide])
Recombinant FSH (Gonal-F or Puregon)








IT: 36.0 (26.5-45.9) 
DT: 35.5(26.2-43.9) 
(P = .001)
Three GnRH analog protocols were used:
(a) Short GnRH agonist (Synarel) protocol
(b) GnRH agonist starting in the midluteal phase 
of the previous cycle
(c) GnRH antagonist (Cetrotide, Orgalutran) on 
day 5 or when the leading follicle was ≥ 14 mm
In all cases, ovarian stimulation was performed 
with rec FSH (400-600 UI/d) (Gonal, Puregon).
In all cases, the beginning of the cycle could  
be spontaneous or after the intake of 
contraceptive pills (30 μg ethinyl estradiol and 
150 μg levonorgestrel)
Triggering with HCG (Ovidrel or Pregnyl)
(a) Natural cycle
(b) Estradiol valerate 6 mg/ day and 
vaginal progesterone pessaries (400-
800 mg/d) or 8% progesterone gel
NR FET cycles with a prior fresh cycle (“fresh 
cycle- FET” interval = 25-35 d or 50-70 d)
Cases from before 2000 or after 
2014
FET preceded by another FET







RC 198 (118 + 80) IT: 32.8 ± 5.0 DT: 
34.1 ± 5.6
GnRH antagonist or agonist protocols.
Triggering with rec HCG
Modified natural cycle
Ovulation triggering with hCG
Vaginal progesterone: 400 mg 
Utrogestan/24 h or 200 mg 
Endometrin (Ferring) or a single daily 










Huang et al 2019 
(01/2013-12/2016),
China (Shanghai)
RC 2998 (280 + 2718) IT: 30.6 ± 4.3
DT: 30.9 ± 4.2
(a) GnRH agonist short protocol: 0.1 triptorelin 
(Decapeptyl; Ferring)
Ovarian stimulation with 150-225 hMG ( hMG; 
Anhui Fengyuan)
Triggering with 5000-10 000 IU of urinary hCG 
( hCG; Lizhu Pharmaceutical Trading)
(b) Progestin-primed ovarian stimulation (10 mg 
medroxyprogesterone acetate (Shanghai Xinyi 
Pharmaceutical)
Ovarian stimulation with hMG (150-225 hMG . 
Triggering with
(a) single use of 5000-1000 IU of urinary hCG,
(b) single dose of triptorelin (0.1-0.2 mg) or
(c) dual trigger with 1,000 IU of urinary hCG 
and 0.1 mg of triptorelin.
(a) Modified natural cycles were 
recommended ( in case of regular 
menstrual cycles)
Ovulation was triggered with 5,000 IU 
of urinary hCG.
Luteal phase was supplemented 
with 40 mg/d of dydrogesterone 
(Duphaston; Abbott)
(b) In irregular cycles 8 mg/d of oral 
micronized estradiol (Fematon, 
Abbott)
Luteal phase was supplemented with 
40 mg/d of oral dydrogesterone and 
400 mg/d of vaginal progesterone 
(Utrogestan)
Day 3-4 cleavage 
stage embryos 
or day 5-6 
blastocysts
Infertile women who underwent their first 
FET after the first IVF/ICSI cycle using 
the freeze-all policy




Uterine anomalies (congenital or 
acquired)
Donor sperm or testicular/epididymal 
sperm.
Moderate or severe ovarian OHSS 
during ovarian stimulation cycle
Embryo cryopreservation > 120 d
Core information missing in medical 
records
Donated oocytes
In vitro maturation oocytes
PGD
Kaye et al 2018 (2013-2016), 
USA
RC 344 (80 + 264) IT: 33.6 ± 3.8
DT: 33.52 ± 3.7
GnRH antagonist or agonist (leuprolide) + rFSH 
and/or, hMG (Gonal-F, Follistim, Menopur) + 
hCG (Pregnyl or Novarel) or GnRH agonist or 
both
Natural cycle and vaginal 
progesterone (Crinone; Merck; or 
Endometrin; Ferring)
or
GnRH agonist downregulation + oral 
and/or transdermal 
estradiol + intramuscular 
progesterone
Blastocyst Age: 18-40 y
(a) FET after a previous ovarian stimulation 
cycle with one failed fresh ET
(b) Freeze-all protocol (PGD, ovarian 
hyperresponse/ OHSS risk, progesterone 
rise, planned surgery, pregnancy 
contraindication, lack of suitable D5 with 
blastocyst cryopreservation on day 6, 
patient preference)
Patients without a stimulation cycle 
before FET (donated oocytes).
Patients in whom embryo freezing 
was performed 120 or more days 
before the FET
Endometrial biopsy or endometrial 
scratching in the cycle prior to ET




Number of cycles 
(immediate + delayed 
transfers) Age (y) OPU cycle management
Endometrial preparation/ luteal 
phase support
Day of embryo 
development Inclusion criteria Exclusion criteria





IT: 34.7 ± 4.13 
DT: 35.3 ± 3.98 
(P = .067)
GnRH antagonist or GnR agonist protocol, 
exogenous gonadotropins and GnRH agonist 
(triptorelin) or rhCG (Ovitrelle)
Estradiol valerate (6 mg) or 
transdermal estradiol hemihydrate 
(150 mg/d)
Vaginal micronized progesterone 
(600 mg/d)
Day 3/4 embryos Freeze-all cycles BMI > 30 kg/m2
Endocrine pathologies
Uterine abnormalities
Chronic, autoimmune, or metabolic 
diseases
Testicular sperm extraction
Meiotic chromosomal abnormalities 
in testicular biopsy or altered 
sperm FISH Participation within the 
previous 6 mo, in a clinical trial with 
medication






IT: 36.3 ± 5.5
DT: 36.6 ± 5.6
NR NR Day 5-6 
blastocysts
First FET cycles after unsuccessful fresh 
ET









GnRH Antagonist (Cetrotide) + rFSH (Gonal-F) 
+ hMG (Menopur) + hCG/GnRH agonist 
(Gonapeptyl) or both
GnRH agonist (Lucrin Depot) or 
Contraceptive pill (Ginera) + oral 
estradiol in step-up regime (2-
4-8 mg) + vaginal progesterone gel 
(Crinone)
Blastocysts “Freeze-all" program >42 y













IT: 32.4 ± 4.4 DT: 
32.5 ± 4.3 (P = .69)
GnRH antagonist (Cetrotide or Ganirelix) 
+ rFSH (Gonal-F, Puregon, Elonva) + HMG 
(Menopur) + HCG
Estradiol valerate (2 mg)
Vaginal micronized progesterone
Day 4 embryos 
and day 5/6 
blastocysts
GnRH antagonist for downregulation
hCG alone for triggering
At least one FET after a previous ovarian 




Triggering with GnRh agonists (alone 
or in combination with hCG)
hCG administration for reasons other 
than ovulation triggering
FET cycles performed with 
downregulation with GnRH agonist 














IT: 30.9 ± 4.1 
DT: 31.8 ± 4.2 
(P = .045, OR 0.97)
GnRH Antagonist (Cetrorelix o Ganirelix). rFSH 
(Gonal-F, Puregon, Elonva) + HMG (Menopur )
+ GnRH agonist (Triptorelin)
Estradiol valerate (2 mg)
Vaginal micronized progesterone
D3 and day 5/6 
blastocysts
First FET after a freeze-all protocol. Donated oocytes
In vitro maturation Blastocyst 
biopsy for preimplantation genetic 
diagnosis
Previous cycle with fresh ET 
canceled due to thin endometrium




RC 1540 (385 + 1155) IT: 31.38 ± 5.19 
DT: 30.99 ± 4.45 
(P = .19)
Ultra-short, short, long and modified ultra-long 
GnRH agonist protocol, GnRH antagonist 
protocol, mini-stimulation protocol
Recombinant FSH (Gonal, Merck or Puregon; 
MSD (150-450 IU/d) and urinary hMG (hMG, 
Livzon)
Triggering with GnRH agonist (0.2 mg 
triptorelin; Decapeptyl) or 250 µg rhCG 
(Ovitrelle; Merck)
(a) Artificial cycle (61.7%)
Estradiol valerate (2 mg/ twice daily 
for at least 14-16 d, adjusting the 
dose afterward
Injectable progesterone (20 mg/d)
(b) Natural cycle (29.5%
(c) Stimulation cycle (8.8%)
D3 Age < 45 y
Stimulation cycle completed with a freeze-
all protocol.
D3 cleavage stage embryo transferred
Patients not undergoing a stimulation 
cycle prior to FET
Donated oocytes
Embryos derived from vitrified 
oocytes






RC 129 (67 + 62) IT : 29.9 ± 4.4 DT: 
29.6 ± 4.2
GnRH Agonist (triptorelin: 3.75mg im or 
0.1 mg/d sc ) + rFSH (Gonal-F) and HMG 
(Menogon) and hCG
Estradiol valerate (4-6mg/d)
Vaginal micronized progesterone 
(200-300 mg/d) or intramuscular 
progesterone
D 3 and D5 First FET cycles after fresh ET with 
negative β-hCG
Age 20-38 y
FET of 1-2 vitrified embryos
≤ 3 previous ET
Artificial cycle for FET
Severe OHSS
PGD
Abbreviations: D3, day 3 cleavage embryo; D5, day 5 blastocysts, DT, delayed transfer; ET, embryo transfer; IT, immediate transfer; FET, frozen  
embryo transfer, FISH, fluorescence in situ hybridization; hCG, human chorionic gonadotropin; hMG, human menopausal gonadotropin; OHSS,  
ovarian hyperstimulation syndrome; OPU, oocyte pick-up; PGD, preimplantation genetic diagnosis; RC, retrospective cohort; rFSH, recombinant  
follicle stimulating hormone.
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4-8 mg) + vaginal progesterone gel 
(Crinone)
Blastocysts “Freeze-all" program >42 y













IT: 32.4 ± 4.4 DT: 
32.5 ± 4.3 (P = .69)
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IT: 30.9 ± 4.1 
DT: 31.8 ± 4.2 
(P = .045, OR 0.97)
GnRH Antagonist (Cetrorelix o Ganirelix). rFSH 
(Gonal-F, Puregon, Elonva) + HMG (Menopur )
+ GnRH agonist (Triptorelin)
Estradiol valerate (2 mg)
Vaginal micronized progesterone
D3 and day 5/6 
blastocysts
First FET after a freeze-all protocol. Donated oocytes
In vitro maturation Blastocyst 
biopsy for preimplantation genetic 
diagnosis
Previous cycle with fresh ET 
canceled due to thin endometrium




RC 1540 (385 + 1155) IT: 31.38 ± 5.19 
DT: 30.99 ± 4.45 
(P = .19)
Ultra-short, short, long and modified ultra-long 
GnRH agonist protocol, GnRH antagonist 
protocol, mini-stimulation protocol
Recombinant FSH (Gonal, Merck or Puregon; 
MSD (150-450 IU/d) and urinary hMG (hMG, 
Livzon)
Triggering with GnRH agonist (0.2 mg 
triptorelin; Decapeptyl) or 250 µg rhCG 
(Ovitrelle; Merck)
(a) Artificial cycle (61.7%)
Estradiol valerate (2 mg/ twice daily 
for at least 14-16 d, adjusting the 
dose afterward
Injectable progesterone (20 mg/d)
(b) Natural cycle (29.5%
(c) Stimulation cycle (8.8%)
D3 Age < 45 y
Stimulation cycle completed with a freeze-
all protocol.
D3 cleavage stage embryo transferred
Patients not undergoing a stimulation 
cycle prior to FET
Donated oocytes
Embryos derived from vitrified 
oocytes






RC 129 (67 + 62) IT : 29.9 ± 4.4 DT: 
29.6 ± 4.2
GnRH Agonist (triptorelin: 3.75mg im or 
0.1 mg/d sc ) + rFSH (Gonal-F) and HMG 
(Menogon) and hCG
Estradiol valerate (4-6mg/d)
Vaginal micronized progesterone 
(200-300 mg/d) or intramuscular 
progesterone
D 3 and D5 First FET cycles after fresh ET with 
negative β-hCG
Age 20-38 y
FET of 1-2 vitrified embryos
≤ 3 previous ET
Artificial cycle for FET
Severe OHSS
PGD
Abbreviations: D3, day 3 cleavage embryo; D5, day 5 blastocysts, DT, delayed transfer; ET, embryo transfer; IT, immediate transfer; FET, frozen  
embryo transfer, FISH, fluorescence in situ hybridization; hCG, human chorionic gonadotropin; hMG, human menopausal gonadotropin; OHSS,  
ovarian hyperstimulation syndrome; OPU, oocyte pick-up; PGD, preimplantation genetic diagnosis; RC, retrospective cohort; rFSH, recombinant  
follicle stimulating hormone.
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F I G U R E  2   Comparison of (A) maternal 
age, (B) oocytes retrieved, and  
(C) embryos transferred in the immediate 
and delayed FET. No significant 
differences were observed. REML, 
restricted maximum likelihood [Colour 
figure can be viewed at wileyonlinelibrary.
com]
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3.3 | IVF outcomes
3.3.1 | Implantation rate (IR)
The IR was reported in five of the studies,19,20,22-24 one of them24 
being the study that reported results in two populations sepa-
rately: GnRH agonist and GnRH antagonist groups. In one case, 
the authors24 were contacted to correct an inaccuracy in the data 
(Figure 3A).
The IR was defined differently in three studies as follows: the 
number of gestational sacs visualized on transvaginal ultrasound 
divided by the number of embryos transferred,19 the percentage 
of gestational sacs per total number of embryos transferred,22 or 
the number of embryos transferred that develop to the stage of 
ultrasound documented gestational sac, divided by the number of 
transferred embryos, calculated for each woman.20 In the other two 
studies, IR was not defined23,24
In one study, the IR was significantly higher in the immediate 
group,19 and in another, it was significantly higher in the delayed 
group.22 There was statistically significant heterogeneity between the 
studies included (Cochran's q = 22.94, P < .001), I2 = 90.7%. Notably, 
the study by Volordarsky-Perel et al reported results quite divergent 
from those of the others. The meta-analysis obtained a similar RR in 
the immediate and delayed groups (RR = 0.98 [0.83-1.16], P = .826).
For subanalysis by embryo development stage (cleavage em-
bryos; blastocysts; cleavage embryo or blastocysts), there was only 
F I G U R E  3   (A) Meta-analysis of studies reporting implantation rates by FET interval. Meta-analysis of the data from 6 included series 
(5 publications) that reported implantation rate as an outcome showed that there were no significant differences between immediate 
and delayed FETs. (B) Meta-analysis of studies reporting biochemical pregnancy rates by FET interval. Meta-analysis of the data from 5 
publications that reported biochemical pregnancy rate as an outcome showed a RR of 1.08 (CI 1.00-1.18) in favor of immediate FET. REML, 
restricted maximum likelihood [Colour figure can be viewed at wileyonlinelibrary.com]
154  |     MATORRAS eT Al.
more than one publication for the subgroup of studies including both 
cleavage embryos and blastocysts. In this meta-analysis, no differ-
ences reached statistical significance (Figure S1).
Similarly, for subanalysis by FET indication (freeze-all, FET after 
failed fresh transfer, both), there was only more than one publication 
in the case of freeze-all cycles. Again, no differences reached signif-
icance (Figure S2).
3.3.2 | Biochemical pregnancy rate
Of the 12 studies analyzed, 5 provided data on biochemical 
PR12,19,20,23,27 (Figure 3B). In one study, biochemical pregnancy was 
defined as a serum β-hCG level ≥ 5 IU/L at 14 days after FET,19 while 
in the others, no definition was given.20,23,26,27
In four studies, a somewhat higher biochemical PR was observed 
in the immediate group,12,19,20,23 although the difference was only 
statistically significant in one.12 On the other hand, the biochemical 
PR was somewhat higher in the delayed group in one study.27
There was no significant heterogeneity in the data analyzed 
(Cochran's q = 4.56, P = .336), I2 = 24.5%. The meta-analysis showed 
a trend to higher biochemical PRs in the immediate group. The RR 
was 1.08 (CI = 1.00-1.18), P = .056.
For subanalysis by embryo development stage, there were two 
studies concerning cleavage embryos and two concerning studies 
including both cleavage embryos and blastocysts. No significant dif-
ferences were detected (Figure S3).
For subanalysis by FET indication, there was only more than one 
publication concerning freeze-all cycles. This meta-analysis showed 
no significant differences (Figure S4).
3.3.3 | Clinical pregnancy rate
In 11 studies, data were provided on clinical PR, and one of them 
was the study in which data were presented separately for GnRH 
agonist and antagonist groups.24 Thus, 12 populations were consid-
ered (Figure 4A).
The definition of clinical pregnancy differed between the stud-
ies. Some authors defined it as the presence of gestational sac on 
ultrasound at 6-8 weeks24 or at 7 weeks of gestation12,18,26 or as at 
least one gestational sac visualized within the uterus on transvaginal 
ultrasound at 8 weeks of gestation.23 Similarly, in one other study, 
clinical pregnancy was defined as at least one gestational sac with or 
without fetal heart activity at 7 weeks of gestation.19 On the other 
hand, other authors defined clinical pregnancy as an intrauterine 
gestational sac with embryonic cardiac activity at 7 weeks 20 or as 
an intrauterine gestational sac with fetal heart activity on ultrasound 
without specifying the gestational age.9,22 Finally, in two reports, no 
definition was given 21,27
In three studies, significantly higher clinical PRs were reported in 
the immediate group18,19,21 whereas in one, that of Volordasky-Perel 
et al, a higher clinical PR was reported in the delayed group. In the 
other eight series, no significant differences were observed.
From a statistical point of view, there was very significant het-
erogeneity (Cochran's q = 34.97, P < .001), I2 = 68.03%. Again, the 
aforementioned study,22 although small in sample size, obtained re-
sults apparently inconsistent with the other studies.
The meta-analysis showed a trend to somewhat higher clinical 
PRs in the immediate group, but without statistical significance. The 
RR was 1.07 (CI = 0.99-1.15), P = .098.
In the subanalysis by embryo development stage (cleavage em-
bryos; blastocysts; cleavage embryo or blastocysts), the meta-anal-
ysis obtained similar RRs in the immediate and delayed FETs in all 
three categories considered, none of the differences reaching sig-
nificance (Figure S5).
When subanalysis was performed by FET indication (freeze-all, 
FET after failed fresh transfer, both), the meta-analysis showed no 
significant differences between immediate and delayed rates in the 
freeze-all or FET-after-failed-fresh-transfer subgroups (Figure S6). 
Further, as only one study considered both freeze all and FET after 
failed fresh transfer, no meta-analysis could be performed.
3.3.4 | Live birth rate
The live birth rate was reported in 10 studies, one of them present-
ing the data for GnRH agonist and antagonist groups separately 
(Figure 4B).24 As for the other variables of interest, definitions of 
live birth varied between the studies. It was defined as the birth of 
a live infant at >20 weeks of gestation in one study,18 at ≥20 weeks 
of gestation in two,25,27 and at >24 weeks in two.9,22 In contrast, 
in one other study, it was defined as the delivery of a viable in-
fant at ≥24 weeks.19 Other authors also set the cutoff at 24 weeks, 
but additionally considered unknown outcomes (patients lost to 
follow-up) as negative.26 Further, in one study, live birth was de-
fined as the delivery of any viable neonate ≥28 weeks, and twins 
delivered by one mother were counted as one live birth,24 while in 
another, live birth rate was established as the number of live birth 
deliveries per FET.20 Finally, live birth rate was not defined in two 
series.21,23
There were no statistically significant differences in the live birth 
rate between the immediate and delayed groups. The RR was 1.05 
(CI = 0.95-1.15), P = .335. There was statistically significant hetero-
geneity (Cochran's q = 33.8, P < .001), I2 = 72.6%.
In the subanalysis by embryo development stage (cleavage em-
bryos; blastocysts; cleavage embryo or blastocysts), the meta-anal-
ysis obtained similar RRs in the immediate and delayed FETs in all 
three categories considered, none of the differences reaching sig-
nificance (Figure S7).
When the subanalysis was performed by FET indication (freeze-
all, FET after failed fresh transfer, both), the RR of the live birth rate 
in the immediate vs delayed FETs did not differ between the sub-
groups (Figure S8).
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F I G U R E  4   (A) Meta-analysis of studies reporting clinical pregnancy rates by FET interval. Meta-analysis of the data from 11 series (10 
publications) that reported clinical pregnancy rate as an outcome showed that the clinical pregnancy rate was significantly increased in the 
immediate FET. (B) Meta-analysis of studies reporting live birth rates by FET interval. Meta-analysis of the data from 11 series  
(10 publications) that reported live birth rate as an outcome showed that there were no significant differences between immediate and 
delayed FETs. REML, restricted maximum likelihood [Colour figure can be viewed at wileyonlinelibrary.com]
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4  | DISCUSSION
Embryo freezing/thawing is a widely performed technique, either 
in selected patients such as those with hyperstimulation risk,35 en-
dometrial problems,10 or elevated progesterone levels,3 patients 
undergoing preimplantation genetic diagnosis cycles,20,36,37 or in all 
patients as proposed by a number of authors.38-40
One of the arguments in favor of frozen embryo cycles is that 
the endometrium would be more favorable to implantation,41-45 
since it has not been under the influence of high estrogen lev-
els, especially in hyper-responders.20,45 Most of the differences 
in outcomes between fresh ET and FET seem to be due to the 
effect of ovarian stimulation on endometrial receptivity and em-
bryo-endometrium synchrony.46 Nonetheless, it is unknown how 
much time is required for the expression of endometrial genes and 
the immunological environment to return to their prestimulation 
functionality.20 On the other hand, excessively postponing ET 
could increase the stress and the anxiety that usually accompany 
IVF.47-49 Moreover, although only to a small extent, postponing ET 
contributes to increase the time to pregnancy, a parameter that 
is increasingly receiving attention as an important marker of the 
quality of IVF.50,51
There are a number of recommendations regarding the 
management of cycles with frozen/thawed embryos, regard-
ing endometrial preparation, progesterone supplementation, 
cycle monitoring, and implantation window assessment.52-56 
Nonetheless, there is no agreement concerning the usefulness of 
delaying ET.
In our search, from the 520 publications initially retrieved, we 
found 12 fulfilling the inclusion criteria, these including a total of 
17 948 FETs (5443 immediate and 12 505 delayed). Among them, 
there was a remarkable methodological heterogeneity: Six included 
only freeze-all patients,19,20,24-27 four only patients with FET after 
failure of a previous fresh ET,9,12,21,22 and two both freeze-all and 
previously failed fresh transfers.18,23
It should be highlighted that we did not find any prospective 
randomized trials or prospective trials. Regarding their quality as 
assessed by the Newcastle-Ottawa Scale, eight studies obtained 
the maximum score -9 and four scored -7. All of them were ret-
rospective, and all of them were single-center studies, except 
one that included two centers.12 On the other hand, there were 
marked differences in cycle management, both in the OPU cycle 
and in the cryotransfer cycle. In cryotransfer cycles, the most 
commonly used treatment was estradiol valerianate and micron-
ized progesterone, although the doses used varied. FET was con-
sidered immediate when performed during the first menstrual 
cycle following the cycle in which OPU or EF had been performed. 
On the other hand, transfer was considered delayed when the ET 
was performed during the second menstrual cycle after OPU/EF 
or later.
In seven of the studies reviewed, no differences were reported 
in any of the IFV outcome parameters.9,12,23-27 At least one IVF out-
come parameter was better in the delayed transfer group in just one 
study,22 while at least one such parameter was better in the imme-
diate transfer group in four studies.18-21 In one of these four, how-
ever, the differences disappeared in multivariate analysis,20 and in 
another, no multivariate analysis was performed.21
Since the studies reviewed were not randomized, we performed 
a separate analysis of three of the most important prognostic factors 
in IVF, namely maternal age,57,58 the number of oocytes retrieved,59 
and the number of embryos transferred.60,61 All of them were very 
similar in the immediate and delayed transfer groups, and hence, 
these were ruled out as confounding factors.
Five studies reported the IR. Better results were obtained in im-
mediate FET in one study 19 and in delayed FET in another,22 while 
no differences were seen in the other three.20,23,24 The meta-anal-
ysis showed similar IRs in the immediate and delayed FET groups 
(RR = 0.98; CI = 0.83-1.16).
Concerning biochemical PR, data were given also in five re-
ports.12,19,20,23,27 The meta-analysis revealed that there was a trend 
to higher biochemical PRs in the immediate group. The RR was 1.08 
(CI = 1.00-1.18).
Regarding clinical PR, data were provided on 12 series from 10 
publications.9,12,18-24,26,27 Two studies found significantly higher 
clinical PRs in the immediate group,19,21 whereas one observed a 
higher clinical PR in the delayed group.22 In the other eight series, 
no significant differences were observed. Our meta-analysis re-
vealed that in the immediate FET the clinical pregnancy rate was 
somewhat higher, with the lower CI close to the unit (RR = 1.07: 
CI = 0.99-1.15).
Concerning live birth rate, the gold standard outcome parameter, 
data were provided in 11 series from 10 publications.9,18-20,22-27 In 
three series, the live birth rate was significantly higher in immediate 
FET,18-20 and in one, it was significantly higher in delayed FET.22 Our 
meta-analysis reported similar live birth rates in the immediate and 
delayed FET groups. The RR was 1.05 (CI = 0.95-1.15).
In brief, none of the IVF outcome parameters studied was better 
in delayed FET than in immediate FET. On the contrary, clinical PR 
and biochemical PR were somewhat higher in the immediate FET, 
but p values were not significant (P = .098). Therefore, our analysis 
fails to confirm the theoretical beneficial effects (more receptive en-
dometrium, resting ovaries) of waiting ≥ one cycle. Indeed, it could 
be speculated that there could be a rebound effect similar to that 
described in the ovary62,63 or with the growth of myomas after stop-
ping medical GnRH analog treatment.64
When we performed meta-analyses concerning embryo devel-
opment stage and FET indication (freeze-all, FET after failed fresh 
transfer, or both), results were similar in immediate and delayed FETs.
From our study, it is clear that systematically delaying FET does 
not offer benefits. First at all, immediate transfer is associated with 
a nonsignificant trend to better clinical PR. Moreover, it also avoids 
the psychological effects of prolonging the stress on prospective 
parents and, in any case, avoids delaying either the pregnancy or a 
new attempt if the current attempt has not been successful. Finally, 
it should be noted that the studies included have limitations, particu-
larly due to their retrospective and non-randomized nature.
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